Acura Pharmaceuticals Reports 3rd Qtr 2010 Financial Results And Product Development Update
All of our opioid product candidates utilizing Aversion® Technology (with or without niacin) are encompassed by two issued U.S. patents, which in combination with our anticipated product labeling and drug product listing strategies are anticipated to provide our opioid products licensed to King with protection from generic competition through the expiration of our patents in 2025.
Impede ™ Technology
We have developed a pseudoephedrine hydrochloride (PSE) tablet product candidate utilizing our Impede ® Technology. Impede™ Technology utilizes a proprietary mixture of functional inactive ingredients intended to limit or impede extraction of PSE from the tablets for use as a starting material in producing the illicit drug methamphetamine. The unique mixture of inactive ingredients in the Impede ® PSE product candidate are generally recognized as safe.
We sponsored an independent pharmaceutical laboratory test of our Impede ™ PSE tablets compared to Sudafed®* brand PSE tablets in an attempt to extract PSE from 100 x 30 mg tablets for conversion to methamphetamine using what we believe to be the three most commonly used conversion processes. The results of these tests demonstrated that while PSE was readily extracted from Sudafed® tablets, Impede ® PSE effectively impeded the extraction of the PSE for conversion into methamphetamine. We are evaluating commercialization strategies for our Impede ® PSE Tablets.*Sudafed® is a registered trademark of Johnson and Johnson Corporation Tender Offer by Pfizer, Inc. to Acquire All Outstanding Shares of King Pharmaceuticals, Inc. On October 12, 2010 Pfizer, Inc. and King Pharmaceuticals, Inc. announced a tender offer by Pfizer to acquire all of the outstanding shares of King. Pfizer and King are targeting a late fourth quarter 2010 or first quarter 2011 closing assuming execution of the tender process and receipt of the appropriate regulatory clearances. Assuming this tender offer is successful, and depending on the structure of the Pfizer/King transaction, Pfizer will assume King's obligations under the King Agreement (if King does not survive as a subsidiary of Pfizer) or King will remain the responsible party under the Agreement (if King survives as a subsidiary of Pfizer).
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts